Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.

Plasma sIl-2R and sCD8 levels of 12 patients with renal cell carcinoma were determined before and during subcutaneous rIl-2 therapy. Patients with a complete/partial remission showed a significantly stronger initial increase of sCD8 compared to patients with stable disease or tumour progression.

Detalles Bibliográficos
Autores principales: Martens, A., Janssen, R. A., Sleijfer, D. T., Heijn, A. A., Mulder, N. H., The, T. H., de Leij, L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968458/
https://www.ncbi.nlm.nih.gov/pubmed/8494709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968458/
https://www.ncbi.nlm.nih.gov/pubmed/8494709

Ejemplares similares